Literature DB >> 23618075

Serum hepcidin: indication of its role as an "acute phase" marker in febrile children.

Lydia Kossiva1, Alexandra Soldatou, Dimitrios I Gourgiotis, Lamprini Stamati, Charalampos Tsentidis.   

Abstract

BACKGROUND: Hepcidin is classified as a type II acute phase protein; its production is a component of the innate immune response to infections.
OBJECTIVE: To evaluate the alterations of serum hepcidin in children during and following an acute febrile infection.
MATERIALS AND METHODS: 22 children with fever of acute onset (< 6 hours) admitted to the 2nd Department of Pediatrics-University of Athens. Based on clinical and laboratory findings our sample formed two groups: the viral infection group (13 children) and the bacterial infection group (9 children). Hepcidin, ferritin and serum iron measurements were performed in all subjects.
RESULTS: Serum hepcidin values did not differ notably between children with viral and bacterial infection, but a significant reduction of hepcidin was noted in both groups post-infection.
CONCLUSION: Our study provides clinical pediatric data on the role of hepcidin in the face of an acute infection. In our sample of children, hepcidin was found to rise during the acute infection and fall post-infection.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23618075      PMCID: PMC3660274          DOI: 10.1186/1824-7288-39-25

Source DB:  PubMed          Journal:  Ital J Pediatr        ISSN: 1720-8424            Impact factor:   2.638


Introduction

Hepcidin is a cytokine-induced antimicrobial peptide produced in the liver that principally regulates the homeostasis of iron concentration. Although its production can be induced by multiple stimuli, IL-6 is considered its dominant upregulator [1]. Thus hepcidin could be classified as a type II acute phase protein. The induction of hepcidin is a component of the innate immune response to infections; it decreases extracellular iron levels reducing iron availability to invading microorganisms [2]. Most studies investigate the regulation and potential roles of hepcidin in animal models [3,4]. Although hepcidin plays a key role in the development of anaemia associated with inflammation and chronic disease, there are only a few clinical studies that examine hepcidin alterations in acute or chronic infections. However, there are not sufficient data in children to validate the use of hepcidin levels in clinical algorithms for the diagnosis of acute infection. The evaluation and treatment of children with fever without a source is a challenging and controversial clinical problem [5]. Although most well appearing children with fever have benign viral illnesses, fever might represent the first sign of occult bacteremia and subsequent serious bacterial infection [6,7]. Discrimination based on clinical criteria has not been sufficient to determine management [8]. A number of large prospective studies have established criteria to accurately identify children warranting presumptive antibiotic therapy [9,10]. Traditional laboratory screening tests include total white blood cell count, absolute neutrophil count, band to neutrophil ratio and C-reactive protein [11-13]. The use of other acute phase reactants, such as procalcitonin and IL-6, to ameliorate the sensitivity of the screen resulted in increased use of antibiotics [14-17]. During an acute-phase reaction there are dramatic changes in iron metabolism. Previous studies have demonstrated differences in serum iron parameters in children with acute bacterial versus viral infections [18]. We hypothesized that the comparison of hepcidin levels of children convalescing from bacterial and viral infections would not yield significant differences enhancing the role of hepcidin as an acute reactant protein. Thus the aim of the present study was to evaluate the alterations of serum hepcidin not only during the acute febrile phase but also post-infection.

Materials and methods

This longitudinal study was conducted during a three-year period between 2008 and 2011. Children of Greek origin and nationality participated voluntarily in the study. Informed consent from parents was obtained in advance. The Ethics Committee of our Hospital and the University of Athens Medical School approved the research protocol. Among 45 patients admitted to the 2nd Department of Pediatrics-University of Athens, 22 children were enrolled in the study. The subjects’ parents filled in a detailed questionnaire, with specific attention any history of anemia, chronic illness and folic acid or iron dietary supplementation. Children receiving antibiotic treatment or dietary iron supplementation as well as children with history of chronic disease or other co-morbidities were excluded from the study (18 patients). The remaining 5 febrile patients were also excluded since their infection could not be classified as viral or bacterial. All participating children underwent thorough physical examination. The study population consisted of 22 infants and children (13 boys, mean age 28.06 ± 37.64 months, range 1 to 144 months) presenting with fever of acute onset (< 6 hours). Full blood count with differential, routine biochemical studies, C-reactive protein, hepcidin, ferritin and serum iron measurements were performed in all subjects at the time of presentation and 4 weeks later, using standard methods by the same laboratory. The hepcidin concentration samples were stored at -80°C for 5 to 10 months before analysis. Serum hepcidin-25 isoform measurements were performed by using a specific ELISA kit (DRG INTERNATIONAL Inc. 1167 U.S Highway 22 East, Mountainside, NJ 07092 USA) according to the manufacturer’s instructions [19]. Based on clinical and laboratory findings our sample was divided into two groups: the viral infection group (13 children) and the bacterial infection group (9 children). The discrimination between bacterial and viral infection was based on the combination of positive blood or urine culture along with C-reactive protein >40 mg/dl and leukocytosis with neutrophilia (white blood cell count >15.000/mm3, neutrophils >60%). The bacterial pathogens isolated were: strep. pneumoniae, Esherichia Coli, Klebsiella pneumoniae, staph aureus. The diagnosis of viral infection was based on either positive polymerase chain reaction (PCR) test or positive IgM antibodies for a specific viral agent (Epstein-Barr virus, cytomegalovirus, coxsackie virus, adenovirus). The clinical spectrum of febrile illnesses included upper or lower respiratory truct infections, urinary truct infections, occult bacteremia, gastroenteritis and cervical lymphadenitis.

Statistical analysis

All statistical analyses and data management were performed using STATA for Windows v 8.5, (StataCorp, Texas, USA, 2006). Data are expressed as Mean ± SD, median. Our study population formed two groups, as mentioned above, the viral infection and bacterial infection groups. Each study variable was measured during the infection (variable 1) and after the infection (variable 2). Data between the two groups (variable X-viral group vs. variable X-bacterial group) were compared using non-parametric Mann-Whitney U test (independent samples). Data within each group (variable X1 vs. variable X2) were compared using non-parametric Wilcoxon paired test (paired samples). We also calculated the difference between variable 1 and variable 2 as ΔvarX = varX1-varX2 within each group and we compared these differences between the two groups (ΔvarX-viral group vs ΔvarX-bacterial group) using non-parametric Mann-Whitney U test (independent samples). P < 0.05 was considered significant.

Results

All study variables are presented in Table 1. Significant differences are hereupon noted in detail. Serum hepcidin values were not notably different between children with viral and bacterial infection, but a significant reduction of hepcidin was noted in both groups post-infection. Serum ferritin values were similar among children belonging to the two groups; however, serum iron levels were found significantly lower only during the acute phase of bacterial infections. Within each group there were significant differences in ferritin and iron levels observed during and after infection. Significant increases in hemoglobin and hematocrit values were noted post-bacterial infection. The difference in hematocrit (Δhct) was significantly greater in the bacterial infection group as well as the difference in MCHC and reticulocyte percentages. As expected, initial ESR values were significantly higher in the bacterial infection group, resulting in a greater difference of ΕSR (ΔESR) than in the viral infection group. Similar changes were observed in WBC and neutrophil count, with higher initial values and greater differences (ΔWBC and ΔN) found in children with bacterial infections. Within each individual group initial lymphocyte count value was significantly lower, while the difference in monocyte count (ΔM) was significantly greater in the viral infection group. Initial CRP value was considerably higher in children with bacterial infections, leading to a greater difference (ΔCRP) in this group compared to the viral infection group. Differences in platelet counts within each group were significant.
Table 1

Characteristics of study population groups

Δvar = var1-var2Viral infection (n = 13)Bacterial infection (n = 9)P*
Age (months)
22.8(±31.75), 8.5 (1 ~ 108)
35.66(±45.79), 18 (2 ~ 144)
 
Male gender (%)
7(53.85%)
6(66.67%)
 
Hepcidin1
90.52(±50.97), 79.44(11.42 ~ 210.18)
72.63(±39.95), 74.10(10.61 ~ 133.8)
0.48
Hepcidin2
53.18(±22.46), 46.17(27.12 ~ 100.73)
42.34(±28.83), 33.14(18.39 ~ 115.73)
0.12
Δhepcidin(1 → 2)
37.34(±59.89), 33.48(-89 ~ 178.74)
30.28(±38.25), 34.99(-39.44 ~ 87.61)
0.86
P**
0.033
0.05
 
Ferritin1
135.98(±106.36), 68.12(30.1 ~ 333.3)
160.01(±117.97), 106.5(73.57 ~ 457.3)
0.24
Ferritin2
50.66(±37.55), 34.5(14 ~ 160)
67.65(±54.01), 39.3(12.4 ~ 173)
0.5
Δferritin(1 → 2)
85.31(±106.86), 35.58(-25.9 ~ 292.58)
92.36(±142.80), 51.7(-69 ~ 421.95)
0.71
P**
0.0046
0.05
 
Serum iron1
29.69(±17.07), 28(9 ~ 69)
15.66(±4.58), 16(10 ~ 25)
0.015
Serum iron 2
47.69(±20.34), 46(21 ~ 76)
46.33(±27.83), 42(18 ~ 115)
0.61
ΔSerum iron (1 → 2)
-18(±29.76), -17(-67 ~ 48)
-30.66(±28.35), -24(-98 ~ 7)
0.24
P**
0.039
0.01
 
Hb1(gr/dl)
11.74(±1.91), 11.7(8.1 ~ 15.5)
11.4(±1.24), 11(10.2 ~ 13.7)
0.59
Hb2 (gr/dl)
11.93(±0.92), 11.8(10.6 ~ 13.7)
12.66(±0.87), 12.1(11.7 ~ 13.9)
0.065
ΔHb(1 → 2)
-0.19(±1.63), -0.69(-2.5 ~ 3.7)
-1.26(±0.95), -1.1(-3.4 ~ -0.19)
0.17
P**
0.46
0.007
 
Hct1 (%)
35.82(±5.62), 35.8(24.6 ~ 45.9)
34.5(±3.74), 32.9(30.3 ~ 41)
0.48
Hct2 (%)
35.30(±2.71), 35(32 ~ 40.5)
38.53(±2.48), 38.7(35.6 ~ 42)
0.01
Δhct(1 → 2)
0.51(±4.65), -0.70(-7.9 ~ 10.7)
-4.03(±3.02), -3.1(-10.4 ~ -1)
0.01
P**
0.86
0.007
 
MCHC1
29.84(±1.58), 30(26 ~ 32.8)
29.36(±1.33), 29(27.5 ~ 31.3)
0.29
MCHC2
30.23(±1.20), 30(28 ~ 32)
30.36(±1.13), 30.2(28 ~ 32.1)
0.68
Δmchc(1 → 2)
-0.38(±1.41), -0.5(-3 ~ 2)
-1.0(±1.15), -1(-3 ~ 0.5)
0.34
P**
0.32
0.028
 
reticulocytes1(%)
1.21(±0.66), 1(0.5 ~ 2.7)
1.6(±0.64), 1.5(0.6 ~ 2.4)
0.16
reticulocytes 2 (%)
0.86(±0.35), 0.8(0.3 ~ 1.4)
0.8(±0.36), 0.7(0.3 ~ 1.6)
0.66
Δreticulocytes (1 → 2)
0.35(±0.74), 0.3(-0.8 ~ 2.1)
0.8(±0.64), 0.6(0–1.7)
0.13
P**
0.10
0.012
 
ESR1 (mm/1 h)
17.38(±8.11), 15(5 ~ 31)
37.66(±14.04), 38(19 ~ 70)
0.0007
ESR2 (mm/1 h)
11.38(±8.7), 9(4 ~ 35)
12.44(±8.5), 10(4 ~ 30)
0.68
ΔESR(1 → 2)
6.0(±12.32), 3(-15 ~ 26)
25.22(±12.36), 26(8 ~ 49)
0.0033
P**
0.1
0.007
 
WBC1/mm3
10205(±3806), 10100(4200 ~ 18200)
23133(±13813), 17400(9300 ~ 50100)
0.005
WBC2/mm3
10100(±3003), 8900(6000 ~ 16800)
10855(±5008), 10400(4700 ~ 21100)
0.86
Δwbc(1 → 2)
115(±4306), 200(-6300 ~ 9700)
12277(±12920), 7700(-4000 ~ 34100)
0.016
P**
0.94
0.02
 
N1 (%)
47.38(±24.59), 54(11 ~ 89)
69.55(±16.43), 66(40 ~ 89)
0.02
N2 (%)
37.07(±11.62), 35(21 ~ 63)
37.17(±15.87), 41(10 ~ 55)
0.73
ΔN(1 → 2)
10.3(±18.19), 16(-24 ~ 33)
37.37(±18.42), 37(-1 ~ 56)
0.01
P**
0.063
0.0109
 
L1 (%)
37.3(±23.08), 33(5 ~ 72)
19.88(±10.44), 23(6 ~ 33)
0.08
L2 (%)
49.61(±14.20), 52(27 ~ 72)
48.63(±18.18), 45(32 ~ 82.5)
0.78
ΔL(1 → 2)
-12.3(±18.71), -17(-39 ~ 24)
-28.74(±16.85), -28(-55.5 ~ -7)
0.065
P**
0.042
0.007
 
M1 (%)
12.38(±5.79), 12(6 ~ 24)
8.66(±5.52), 6(3 ~ 20)
0.069
M2 (%)
8.23(±2.80), 7(4 ~ 13)
10.03(±3.45), 10(6 ~ 16)
0.19
ΔM(1 → 2)
4.15(±6.4), 2(-4 ~ 18)
-1.36(±6.39), -3(-10 ~ 10)
0.034
P**
0.072
0.4
 
CRP1 (mg/dl)
17.07(±24.69), 12(0 ~ 93)
100.88(±59.50), 92(24 ~ 178)
0.0006
CRP2 (mg/dl)
4.57(±5.48), 1(0 ~ 17)
5.11(±9.51), 2(0 ~ 30)
0.91
Δcrp(1 → 2)
12.5(±23.08), 7(-9 ~ 82)
95.77(±64.87), 90.5(-6 ~ 173)
0.0037
P**
0.022
0.0109
 
PLT1 /mm3
382923(±162607), 335000(191000 ~ 758000)
465444(±162687), 438000(215000 ~ 709000)
0.19
PLT2 /mm3
275538(±63602), 278000(198000 ~ 403000)
302555(±48844), 303000(230000 ~ 383000)
0.25
ΔPLT(1 → 2)
107384(±137673), 44000(-84000 ~ 355000)
162888(±132197), 120000(-41000 ~ 326000)
0.3
P**0.0150.0109 

P* Mann-Whitney U test.

P** Wilcoxon paired test.

Data are expressed as mean (±SD), median.

Characteristics of study population groups P* Mann-Whitney U test. P** Wilcoxon paired test. Data are expressed as mean (±SD), median.

Discussion

Our study provides clinical pediatric data on the role of hepcidin in the face of an acute infection. In our sample of children with viral and bacterial infections, hepcidin was found to rise during the acute infection and fall post-infection. Hepcidin is a 25-amino acid peptide synthesized by hepatocytes, secreted into the bloodstream and cleared from the circulation by the kidneys. It regulates the levels of circulating iron by controlling the absorption of dietary iron and the release of iron from macrophages and hepatocytes. Hepcidin synthesis is regulated by both physiologic and pathologic mechanisms. In peripheral blood leads in decrease in hepcidin concentration In hypoxia, iron deficiency, anemia or ineffective erythropoiesis, increased iron demand in the peripheral blood leads to a decrease in hepcidin concentation. The latter results in increased absorption of iron from the intestine and increased release from iron-storing cells by binding, internalization and degradation of the cellular iron efflux molecule, ferroportin [20]. On the contrary, infection, chronic inflammation and iron overload result in increases of hepcidin concentration and subsequent decreases in circulating iron; in hereditary hemochromatosis a mutated hepcidin gene results in deficient excretion of the molecule leading to iron accumulation. Most studies examining the role of hepcidin as an acute phase protein are based on in vitro and animal models. Specifically, hepcidin has been well described as a hepatic acute phase protein in laboratory studies similarly to ferritin. Ferritin rises during acute infections resulting in unreliable measurements as an iron parameter. Murine models indicate that hepcidin is a component of the innate immune response to acute infection with anti-inflammatory properties and a potential marker of billiary stress [21,22]. Experimental deliberate exposure to bacterial agents in salmon and rats has demonstrated the up regulation of hepcidin [23,24]. Limited research data from adult populations attempt to elucidate the role of hepcidin in the common cold, iron metabolism disorders, chronic kidney disease, chronic hepatitis C and kidney transplant recipients [25-27]. In an adult patient population study group, hepcidin was demonstrated as a potentially useful marker that reflects the degree of billiary inflammation in cholecystitis and primary sclerosing cholangitis (PSC) - associated bacterial infection. To the best of our knowledge, there are only two studies examining the role of serum hepcidin during chronic infections in pediatric populations. One showed a correlation of increased hepcidin levels with asymptomatic malarial parasitemia (P. falciparum and P. vivax), despite the absence of a measurable acute phase response [28]. The second failed to demonstrate significant alterations of hepcidin levels in children with chronic gastrointestinal infections (H. pylori and helminthes) [29]. The main limitation of our study was the small size of sample. However, since weak statistical significance was achieved, a larger sample is needed to clarify the changes in hepcidin levels. The comparison of its levels in children convalescing from bacterial and viral infections did not yield significant differences. Interestingly, low levels of serum iron were shown in bacterial infections. These findings generate thoughts about the existence of other biological parameters involved in the regulation of iron metabolism during acute infection.

Conclusions

The present study provides preliminary data on the role of hepcidin as an acute reaction marker in febrile children. Further studies are needed to clarify our findings, ideally in a larger sample of febrile children. In addition other biological parameters involved in iron metabolism could be investigated.

Abbreviations

Hb: Hemoglobin; Ht: Hematocrit; MCHC: Mean corposcular hemoglobin concentration; ESR: Erythrocyte sedimentation rate; WBC: White blood cells; N: Neutrophils; L: Lymphocytes; M: Monocytes; CRP: C-reactive protein; PLT: Platelets.

Competing interests

The authors declare that they have no competing interests.

Authors’ contributions

LK: design the study and enroll the subjects. AS: participated in the selection of the subjects. DG: measured the serum hepcidin samples. LS: measured the serum hepcidin samples. CT: did the statistical analysis. All authors read and approved the final manuscript.
  29 in total

1.  Serum hepcidin and ferritin to iron ratio in evaluation of bacterial versus viral infections in children: a single-center study.

Authors:  Lydia Kossiva; Dimitrios I Gourgiotis; Charalampos Tsentidis; Theodora Anastasiou; Antonis Marmarinos; Helen Vasilenko; Triantafyllia Sdogou; Helen Georgouli
Journal:  Pediatr Infect Dis J       Date:  2012-08       Impact factor: 2.129

2.  Tumor necrosis factor-alpha, interleukin-1 beta, and interleukin-6 levels in febrile, young children with and without occult bacteremia.

Authors:  R T Strait; K J Kelly; V P Kurup
Journal:  Pediatrics       Date:  1999-12       Impact factor: 7.124

3.  C-reactive protein in febrile children 1 to 36 months of age with clinically undetectable serious bacterial infection.

Authors:  P N Pulliam; M W Attia; K M Cronan
Journal:  Pediatrics       Date:  2001-12       Impact factor: 7.124

Review 4.  Hepcidin and disorders of iron metabolism.

Authors:  Tomas Ganz; Elizabeta Nemeth
Journal:  Annu Rev Med       Date:  2011       Impact factor: 13.739

5.  Absence of leukocytosis in bacteraemic pneumococcal pneumonia.

Authors:  Victoria Furer; David Raveh; Elie Picard; Shmuel Goldberg; Gabriel Izbicki
Journal:  Prim Care Respir J       Date:  2011-09

6.  Is procalcitonin useful in early diagnosis of serious bacterial infections in children?

Authors:  Sudhin Thayyil; Mohan Shenoy; Mainga Hamaluba; Anil Gupta; John Frater; Ian G Verber
Journal:  Acta Paediatr       Date:  2005-02       Impact factor: 2.299

Review 7.  Hepatic acute phase proteins--regulation by IL-6- and IL-1-type cytokines involving STAT3 and its crosstalk with NF-κB-dependent signaling.

Authors:  Johannes G Bode; Ute Albrecht; Dieter Häussinger; Peter C Heinrich; Fred Schaper
Journal:  Eur J Cell Biol       Date:  2011-11-16       Impact factor: 4.492

8.  Impact of procalcitonin on the management of children aged 1 to 36 months presenting with fever without source: a randomized controlled trial.

Authors:  Sergio Manzano; Benoit Bailey; Jean-Bernard Girodias; Annick Galetto-Lacour; Jocelyne Cousineau; Edgard Delvin
Journal:  Am J Emerg Med       Date:  2010-01-28       Impact factor: 2.469

Review 9.  Management of infants and young children with fever without source.

Authors:  Larry J Baraff
Journal:  Pediatr Ann       Date:  2008-10       Impact factor: 1.132

10.  Hepcidin is an antibacterial, stress-inducible peptide of the biliary system.

Authors:  Pavel Strnad; Peggy Schwarz; Maria C D Rasenack; Ozlem Kucukoglu; Rayan I Habib; Dominik Heuberger; Robert Ehehalt; Michael W Müller; Adolf Stiehl; Guido Adler; Hasan Kulaksiz
Journal:  PLoS One       Date:  2011-01-24       Impact factor: 3.240

View more
  5 in total

1.  Applied value of monitoring serum hepcidin in differential diagnosis of infection versus tumor fevers.

Authors:  Ling Li; Jiang-Guo Zhang; Man-Zhi Zhao; Zhu-Hua Wu; Jian-Xin Song
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2017-04-11

Review 2.  Hepcidin - A novel biomarker with changing trends.

Authors:  Arunava Kali; Marie Victor Pravin Charles; Rathan Shetty Kolkebail Seetharam
Journal:  Pharmacogn Rev       Date:  2015 Jan-Jun

Review 3.  Host Biomarkers for Distinguishing Bacterial from Non-Bacterial Causes of Acute Febrile Illness: A Comprehensive Review.

Authors:  Anokhi J Kapasi; Sabine Dittrich; Iveth J González; Timothy C Rodwell
Journal:  PLoS One       Date:  2016-08-03       Impact factor: 3.240

4.  The amniotic fluid proteome changes with gestational age in normal pregnancy: a cross-sectional study.

Authors:  Gaurav Bhatti; Roberto Romero; Nardhy Gomez-Lopez; Tinnakorn Chaiworapongsa; Eunjung Jung; Francesca Gotsch; Roger Pique-Regi; Percy Pacora; Chaur-Dong Hsu; Mahendra Kavdia; Adi L Tarca
Journal:  Sci Rep       Date:  2022-01-12       Impact factor: 4.996

5.  Hepcidin discriminates sepsis from other critical illness at admission to intensive care.

Authors:  Jon Olinder; Alex Börjesson; Jakob Norrman; Tobias West; Joakim Carlström; Alexander Gustafsson; Martin Annborn; Heiko Herwald; Cecilia Rydén
Journal:  Sci Rep       Date:  2022-09-01       Impact factor: 4.996

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.